Anti-p53 Antibody (3347)

Synthetic peptide corresponding to amino acids at the C-terminus of human p53.

PBS, pH 7.4, 50% glycerol, 0.09% sodium azide.

Liquid

Purified by Protein A affinity chromatography

This antibody is stable for at least one (1) year at -20°C.

For in vitro investigational use only. Not intended for therapeutic or diagnostic applications.

Next Day 2-8°C

This antibody recognizes human p53.

Tumor protein p53, also known as p53, functions as a tumor suppressor, and, as such, p53 has been described as “the guardian of the genome†because of its role in preventing genome mutations. The name p53 describes the apparent molecular mass of the protein as observed in SDS-PAGE analysis. The actual mass of full-length p53, based on the sum of masses of the amino acid residues, is 43.7kDa. The difference is due to the number of proline residues in the protein which slow its migration on SDS-PAGE, thus making it appear heavier than it actually is. The TP53 gene is the most frequently mutated gene (>50%) in human cancer.

Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492). {PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:9840937}.